Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06464926 · ClinicalTrials.gov registry record · NA

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

A NA study of Nausea and Vomiting, sponsored by Enterra Medical.

Recruiting
Registry status
NA
Development phase
148
Enrollment target
17
Study locations

NCT06464926: Recruiting NA study of Nausea and Vomiting, sponsored by Enterra Medical.

NCT06464926 is a NA study of Nausea and Vomiting that is actively recruiting participants, run by Enterra Medical. The registered enrollment target is 148 participants, below the 235-participant average among 17 other Nausea trials with a reported enrollment target (37% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06464926, a NA study of Nausea and Vomiting, is actively recruiting participants, sponsored by Enterra Medical.

RECRUITING
Registry status
NA
Development phase
148 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have normal gastric emptying.

Primary Outcome

As measured by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) nausea severity score

Conditions Studied

Interventions

  • DEVICE Enterra Therapy System

Study Locations (17)

Other

  • UZ Leuven - Leuven
  • Hôpital Louis-Mourier - Colombes
  • Hôpital Edouard Herriot - CHU de Lyon - Lyon
  • CHU de Bordeaux - Pessac
  • CHU de Rouen - Rouen
  • Sahlgrenska Universitetssjukhuset - Gothenburg

California

  • Hoag Hospital - Newport Beach
  • Sutter Health - San Francisco

Arizona

  • Mayo Clinic Arizona - Scottsdale

Florida

  • University of South Florida - Tampa

Illinois

  • Endeavor Health - Evanston

Indiana

  • Indiana University Health - Indianapolis

Kentucky

  • University of Louisville - Louisville

New Jersey

  • Hackensack Meridian - Neptune City

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2025-06-23
Est. Completion 2030-06
Phase NA
Enterra Medical

3 total trials

What NCT06464926 shows while recruiting

NCT06464926 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, below the 235-participant average among 17 other Nausea trials with a reported enrollment target (37% lower).

The record links to 2 conditions, with Nausea appearing as the primary indexed condition, and to 1 intervention - of which Enterra Therapy System is the first listed.

NCT06464926 lists 17 locations in 11 states (Other, California, Arizona).

Frequently Asked Questions

What is clinical trial NCT06464926 about?

NCT06464926 is a clinical study titled "Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)". The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have normal gastric emptying.

What is the current status of trial NCT06464926?

This trial is currently recruiting. It is a NA study. The enrollment target is 148 participants. The study started on 2025-06-23. Estimated completion is 2030-06.

What conditions does trial NCT06464926 study?

This clinical trial studies the following conditions: Nausea, Vomiting.

What interventions are being tested in trial NCT06464926?

The interventions under investigation include: Enterra Therapy System (DEVICE).

Who is sponsoring clinical trial NCT06464926?

This trial is sponsored by Enterra Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06464926 being conducted?

This trial has 17 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nausea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06464926's enrollment target sits among peer trials

148 7th of 17 higher than 11 of 17 other Nausea trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Nausea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00739362 · 148 participants · Phase 2

    Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment

  • NCT03161223 · 148 participants · Phase 1

    Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

  • NCT03858231 · 148 participants · Phase 4

    Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery

  • NCT04486352 · 148 participants · Phase 1

    A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06464926, the US trial registry maintained by the National Library of Medicine. NCT06464926 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.